Cargando…

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

Multiple myeloma (MM) is characterized by a high capacity to induce alterations in the bone remodeling process. The increase in osteoclastogenesis and the suppression of osteoblast formation are both involved in the pathophysiology of the bone lesions in MM. The proteasome inhibitor (PI) bortezomib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Accardi, Fabrizio, Toscani, Denise, Bolzoni, Marina, Dalla Palma, Benedetta, Aversa, Franco, Giuliani, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633537/ https://www.ncbi.nlm.nih.gov/pubmed/26579531 http://dx.doi.org/10.1155/2015/172458

Ejemplares similares

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients
por: Marchica, Valentina, et al.
Publicado: (2019)

Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease
por: Raimondi, Vincenzo, et al.
Publicado: (2022)

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
por: Costa, Federica, et al.
Publicado: (2021)

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
por: Costa, Federica, et al.
Publicado: (2017)

Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy
por: Toscani, Denise, et al.
Publicado: (2018)

CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
por: Costa, Federica, et al.
Publicado: (2019)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

New Insights into Osteogenic and Chondrogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells and Their Potential Clinical Applications for Bone Regeneration in Pediatric Orthopaedics
por: Giuliani, Nicola, et al.
Publicado: (2013)

IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts
por: Bolzoni, Marina, et al.
Publicado: (2017)

Neurofibromatosis type I and multiple myeloma coexistence: A possible link?
por: Accardi, Fabrizio, et al.
Publicado: (2018)

The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease
por: Lungu, Oxana, et al.
Publicado: (2023)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
por: Storti, Paola, et al.
Publicado: (2020)

Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis
por: Raimondo, Stefania, et al.
Publicado: (2019)

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors
por: Nakaue, Emiko, et al.
Publicado: (2023)

Bone Marrow Monocyte / Macrophage Derived Activin A Mediates the Osteoclastogenic Effect of IL-3 in Multiple Myeloma
por: Silbermann, Rebecca, et al.
Publicado: (2013)

NAD(+)-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
por: Horenstein, Alberto L., et al.
Publicado: (2015)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice
por: Wang, Hua, et al.
Publicado: (2018)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
por: Nikesitch, N, et al.
Publicado: (2016)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability
por: Chiu, Martina, et al.
Publicado: (2020)

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS
por: Notarfranchi, L., et al.
Publicado: (2023)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
por: Manda, Sudhir, et al.
Publicado: (2020)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Game of Bones: How Myeloma Manipulates Its Microenvironment
por: Moser-Katz, Tyler, et al.
Publicado: (2021)

Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
por: Ho, Matthew, et al.
Publicado: (2022)

Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results
por: Fazzi, Rita, et al.
Publicado: (2021)

Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy
por: Marchica, Valentina, et al.
Publicado: (2020)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
por: Harmer, Danielle, et al.
Publicado: (2019)

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma
por: Allmeroth, Kira, et al.
Publicado: (2020)

Computational Modeling of Interactions between Multiple Myeloma and the Bone Microenvironment
por: Wang, Yan, et al.
Publicado: (2011)

The role of the bone microenvironment in regulating myeloma residual disease and treatment
por: Dadzie, Terry G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s5ijd1uukmqirtuf22dgnk2jdq